An investment led by former Morrison & Co chief executive Marko Bogoievski and Sir Stephen Tindall’s investment arm K1W1 into local biotech firm Pictor will see the Kiwis partner with a US laboratory to use its test that allows people to see what kind of antibodies they have in the fight against
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
